Background: Minimal manifestation status (MMS) is an important landmark in the treatment of myasthenia gravis (MG), and predictors of MMS induction have rarely been identified in previous studies.
Objective: The objective of this study is to evaluate the clinical factors associated with MMS induction among patients with MG.
Design: This two-step retrospective cohort study with a single center investigated the factors that may be associated with MMS induction and retested these predictors in a test cohort.
Methods: A total of 388 diagnosed MG patients who visited Xiangya Hospital between 1 July 2015 and 1 July 2019 were involved. We performed detailed chart reviews and recorded all cases achieving MMS. Demographics and clinical characteristics were also collected and their relationships to achieving MMS were investigated.
Results: MMS was achieved in 124 patients (50.2%), and the median time to achieve MMS was 26 months. Several factors were found to be associated with MMS induction in exploring cohort, including muscle-specific tyrosine-protein kinase receptor (MuSK) antibody positivity (adjusted hazard ratio, HR = 4.333, 95% confidence interval, CI: 1.862-10.082), isolated ocular involvement (adjusted HR = 1.95, 95% CI: 1.284-2.961), and low baseline quantitative myasthenia gravis score (QMG score; adjusted HR = 2.022, 95% CI: 1.086-3.764). These factors were then retested in the test cohort. Isolated ocular involvement or low baseline QMG scores were factors found to be beneficial for MMS induction were confirmed.
Conclusion: Isolated ocular involvement and low baseline QMG score are predictors of MMS induction in MG patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968991 | PMC |
| http://dx.doi.org/10.1177/17562864221080520 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cyto-Genotoxic Assessment of Sulfoxaflor in Allium cepa Root Cells and DNA Docking Studies.
Microsc Res Tech
January 2025
Molecular Biology and Genetics Department, Faculty of Engineering and Natural Sciences, Uşak University, Uşak, Turkey.
Sulfoxaflor (SFX) is an insecticide that is commonly used for the control of sap-feeding insects. Since SFX is extensively applied globally, it has been implicated in the substantial induction of environmental toxicity. Therefore, in this study, Allium cepa roots have been employed to elucidate the potential cytogenotoxic effects of SFX in non-target cells by examination of mitotic index (MI), chromosomal aberrations (CAs), and DNA damage.
View Article and Find Full Text PDFTamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial.
Lancet Gastroenterol Hepatol
January 2025
Department of Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Milan, Italy.
Background: Tamuzimod (VTX002) is a selective sphingosine 1-phosphate receptor 1 modulator in development for ulcerative colitis. We aimed to assess the safety and efficacy of tamuzimod in patients with moderately-to-severely active ulcerative colitis.
Methods: This double-blind, randomised, placebo-controlled, phase 2 induction trial was conducted at 122 centres across 15 countries in Asia, Europe, and North America.
Influence of Magnetic Stirring and Eutectic Front Velocity on the Solidified Microstructure of Al-18 wt.% Si Alloy.
Materials (Basel)
December 2024
Institute of Physical Metallurgy, Metal Forming & Nanotechnology, University of Miskolc, 3515 Miskolc, Hungary.
The microstructure of hypereutectic Al-Si alloys is crucial in determining their mechanical properties and overall performance in engineering applications. This paper investigates the effect of a rotating magnetic field (RMF) and eutectic front velocity on the microstructure of hypereutectic Al-18 wt.% Si alloy.
View Article and Find Full Text PDFMirikizumab pharmacokinetics and exposure-response in pediatric patients with moderate-to-severe ulcerative colitis.
CPT Pharmacometrics Syst Pharmacol
December 2024
Eli Lilly and Company, Indianapolis, Indiana, USA.
Mirikizumab is a p19-directed anti-interleukin-23 antibody approved for the treatment of adults with moderate-to-severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure-response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate-to-severe UC from the phase II, open-label study SHINE-1 (NCT04004611). PK parameters were analyzed using a model developed previously in adults with fixed-exponent allometry for body weight.
View Article and Find Full Text PDFPerioperative management of patients with mediastinal mass syndrome.
Curr Opin Anaesthesiol
February 2025
Department of Anaesthesiology and Intensive Care Medicine, University Hospital, Otto-von-Guericke University.
Purpose Of The Review: The mediastinal mass syndrome (MMS) can occur after induction of anesthesia, intraoperatively or even days after the surgical procedure. The focus of this review is on the management of pediatric and adult patients with a significant mediastinal mass.
Recent Findings: The age distribution of patients with mediastinal lesions suggests a bimodal shape, with an increased incidence among children under 10 years old and adults aged 60-70 years old.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!